Grants Search Results

Unlike many other pediatric cancers, osteosarcoma has many abnormalities found on genetic analysis of the tumor itself. Dr. Sweet Cordero and colleagues hypothesize that some of these abnormalities could be used to predict what treatment might work best for each specific osteosarcoma patient. For example, many osteosarcomas have genetic alterations that block their ability to "repair" their DNA using specific pathways. One of these defective pathways is called the "homologous repair" pathway and another is called the "alternative lengthening of chromosomes" pathway. The inability of osteosarcoma tumors to repair their DNA using these pathways may make them susceptible to specific drugs. However, it is very likely that these drugs will need to be used in combination and not alone. A key need to advance osteosarcoma patient care is to define and use appropriate model systems to test drugs before using them in patients. This project is combining both preclinical studies in PDX models and a clinical trial to develop new ways to treat osteosarcoma patients with the goal being to improve survival for patients with relapsed and metastatic disease.

This multi-year grant is named for and funded by the Battle Osteosarcoma Hero Fund inspired by and established in honor of Charlotte, Dylan, Tyler and all OsteoWarriors. Led by parents, its mission is to raise funds for promising osteosarcoma precision oncology research to improve treatment options and outcomes for kids battling osteosarcoma.

This grant supports a scientific meeting to plan a clinical trial for osteosarcoma, focused on using genomic data to define subgroups to receive targeted therapy combined with chemotherapy.

Ewing sarcoma is a type of cancer that mostly affects children and your adults. This cancer is caused by a type of mutation in DNA called a translocation. Dr. Sweet-Cordero's Team Clarkie St. Baldrick's Research Grant aims to understand how this translocation, called EWS-FLI1, causes cancer in order to find better therapies for children with this disease.

This grant is named for the Team Clarkie Fund created to honor Clarkie Carroll and funds Ewing’s sarcoma research while stimulating greater awareness and inspiring others to believe pediatric cancer research can and will lead to a cure.

Ewing sarcoma (ES) is one of the most common sarcomas in children, caused by a genetic abnormality called a "chromosomal translocation." This study has two goals. First, to understand the normal function of the protein EWS, to learn about what goes wrong in Ewings tumors. Second, to understand what other genetic events are required to turn normal human cells into Ewing sarcomas. Our approach is to try to combine EWS/FLI-1 expression with other genetic events in the type of human cell that we know gives rise to ES.